Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus

Vitam Horm. 2022:118:457-478. doi: 10.1016/bs.vh.2021.12.005. Epub 2022 Feb 4.

Abstract

The glucagon-like peptide-1 (GLP-1) is a pleiotropic hormone very well known for its incretin effect in the glucose-dependent stimulation of insulin secretion. However, GLP-1 is also produced in the brain, and it displays critical roles in neuroprotection by activating the GLP-1 receptor signaling pathways. GLP-1 enhances learning and memory in the hippocampus, promotes neurogenesis, decreases inflammation and apoptosis, modulates reward behavior, and reduces food intake. Its pharmacokinetics have been improved to enhance the peptide's half-life, enhancing exposure and time of action. The GLP-1 agonists are successfully in clinical use for the treatment of type-2 diabetes, obesity, and clinical evaluation for the treatment of neurodegenerative diseases.

Keywords: Alzheimer's disease; Food reward; Glucagon-like peptide 1; Glucagon-like peptide 1 receptor; Hippocampus; Inflammation; Learning; Memory; Neuroprotection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / metabolism
  • Glucagon-Like Peptide 1* / analogs & derivatives
  • Glucagon-Like Peptide 1* / pharmacology
  • Glucagon-Like Peptide-1 Receptor / agonists
  • Glucagon-Like Peptide-1 Receptor / metabolism
  • Hippocampus / metabolism
  • Humans
  • Incretins / pharmacology
  • Peptide Fragments / metabolism

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Incretins
  • Peptide Fragments
  • Glucagon-Like Peptide 1